Givlaari Effects Sustained Over Time for Patients with Acute Hepatic Porphyria
whitesession / Pixabay

Givlaari Effects Sustained Over Time for Patients with Acute Hepatic Porphyria

  In 2019, Alnylam Pharmaceuticals received FDA approval for Givlaari, the first RNAi therapy for patients with acute hepatic porphyria. Although some were initially worried about the therapy's safety and…

Continue Reading Givlaari Effects Sustained Over Time for Patients with Acute Hepatic Porphyria
David Fajgenbaum Found His Own Drug For Castleman’s Disease. Now He Turns to COVID-19
source: pixabay.com

David Fajgenbaum Found His Own Drug For Castleman’s Disease. Now He Turns to COVID-19

David Fajgenbaum toes the line between patient and doctor. After growing up with a physician as a father, Fajgenbaum chose to follow in his footsteps. His most important lessons came…

Continue Reading David Fajgenbaum Found His Own Drug For Castleman’s Disease. Now He Turns to COVID-19
Close Menu